Interaction of met-enkephalin with human granulocytes

Area of Science:

• Immunology
• Neuroendocrinology
• Cell Biology

Background:

• Human polymorphonuclear leukocytes (PMNs) play crucial roles in immune responses.
• Endogenous opioid peptides, like Met-enkephalin, are known to modulate various physiological processes.

Purpose of the Study:

• To investigate the effects of Met-enkephalin on human PMN cell shape and motility.
• To explore the binding characteristics and metabolic fate of Met-enkephalin in relation to PMNs.

Main Methods:

• Assessing changes in human PMN cell morphology and motility upon exposure to Met-enkephalin.
• Attempting to demonstrate specific binding of radiolabeled Met-enkephalin to PMNs.
• Analyzing the degradation products of Met-enkephalin in the cell medium and subsequent uptake of metabolites.

Main Results:

• Met-enkephalin significantly altered the shape and motility of human PMNs.
• No specific binding of tritium-labeled Met-enkephalin to PMNs was detected.
• Rapid proteolytic degradation of Met-enkephalin occurred, followed by the uptake of labeled tyrosine.
• The responsible peptidase recognized the N-terminal sequence of various endogenous opioid peptides.
• Protease inhibitors bestatin and bacitracin showed minimal effect on Met-enkephalin degradation.

Conclusions:

• Met-enkephalin exerts biological effects on human PMNs, likely through indirect mechanisms.
• The observed effects are not mediated by direct, specific receptor binding on PMNs.
• Degradation of Met-enkephalin by peptidases in the surrounding medium is a significant factor in its interaction with PMNs.